---
name: pharma_strategy_report_hunter
description: å¯»æ‰¾å¹¶æ·±å…¥åˆ†æåŒ»è¯è¡Œä¸šæˆ˜ç•¥æŠ¥å‘Šï¼Œæä¾›å’¨è¯¢é¡¾é—®å¼çš„æ´å¯Ÿã€‚
---

# Pharma Strategy Report Hunter (åŒ»è¯è¡Œç ”çŒæ‰‹)

## æ ¸å¿ƒé€»è¾‘ (The Thought Process)
æ­¤ Skill çš„è®¾è®¡æ—¨åœ¨è§£å†³â€œä¿¡æ¯å™ªéŸ³â€é—®é¢˜ã€‚å’¨è¯¢èƒŒæ™¯çš„å€™é€‰äººæå…¶æŒ‘å‰”ï¼Œä»–ä»¬ä¸éœ€è¦â€œæ–°é—»â€ï¼Œä»–ä»¬éœ€è¦â€œæ·±åº¦æ´å¯Ÿ(Insights)â€ã€‚
å› æ­¤ï¼Œæœ¬ Skill é‡‡ç”¨ **â€œæ¼æ–—å¼â€** ç­›é€‰æœºåˆ¶ï¼š
1.  **ç¬¬ä¸€å±‚ (Source Filter)**: ä»…é€šè¿‡ `site:` æŒ‡ä»¤é”å®š MBB/IQVIA ç­‰é¡¶çº§æœºæ„å®˜ç½‘ï¼Œä»æºå¤´æœç»è¥é”€å·ã€‚
2.  **ç¬¬äºŒå±‚ (Format Filter)**: å¼ºåˆ¶ä½¿ç”¨ `filetype:pdf`ï¼Œå› ä¸ºæ·±åº¦æŠ¥å‘Šé€šå¸¸ä»¥ PDF ç™½çš®ä¹¦å½¢å¼å‘å¸ƒï¼Œç½‘é¡µå¤šä¸ºæµ…å±‚èµ„è®¯ã€‚
3.  **ç¬¬ä¸‰å±‚ (Content Filter)**: è¦æ±‚ AI ä¸åšç®€å•çš„â€œæ‘˜è¦â€ï¼Œè€Œæ˜¯æç‚¼â€œConsulting Implicationsâ€ (å¯¹æˆ˜ç•¥é¡¾é—®æ„å‘³ç€ä»€ä¹ˆ)ã€‚

## æ‰§è¡ŒæŒ‡ä»¤ (Instructions)

### ç¬¬ä¸€æ­¥ï¼šéšæœºèšç„¦ (Randomize Focus)
ä¸ºäº†é¿å…æ¯æ¬¡éƒ½èƒ½çœ‹åˆ°ç›¸åŒçš„æŠ¥å‘Šï¼Œè¯·åœ¨å¼€å§‹æœç´¢å‰ï¼Œå…ˆä»ä»¥ä¸‹ **æˆ˜ç•¥ä¸»é¢˜æ± ** ä¸­**éšæœº**é€‰æ‹©ä¸€ä¸ªä½œä¸ºæœ¬æ¬¡çš„æœç´¢é‡ç‚¹ï¼š
*   **Themes**: [
    Market Access (å‡†å…¥ç­–ç•¥), VBP Impact (é›†é‡‡å½±å“), NRDL Negotiation (åŒ»ä¿è°ˆåˆ¤), DRG/DIP Payment (æ”¯ä»˜æ”¹é©), Pharma R&D Digitalization (ç ”å‘æ•°å­—åŒ–),
    AI in Drug Discovery (AIåˆ¶è¯), Clinical Trial Efficiency (ä¸´åºŠæ•ˆç‡), Decentralized Clinical Trials (DCT), Real World Evidence (RWE), Precision Medicine (ç²¾å‡†åŒ»ç–—),
    Gene Therapy (åŸºå› æ²»ç–—), Cell Therapy (ç»†èƒæ²»ç–—), ADC Drug Market (ADCè¯ç‰©), Biosimilars (ç”Ÿç‰©ç±»ä¼¼è¯), Vaccine Innovation (ç–«è‹—åˆ›æ–°),
    Oncology Trends (è‚¿ç˜¤è¶‹åŠ¿), Immunology Market (å…ç–«å¸‚åœº), Rare Diseases (ç½•è§ç—…), Chronic Disease Management (æ…¢ç—…ç®¡ç†), CNS Trends (ä¸­æ¢ç¥ç»),
    Omnichannel Marketing (å…¨æ¸ é“è¥é”€), Digital Therapeutics (æ•°å­—ç–—æ³•), Patient Centricity (ä»¥æ‚£è€…ä¸ºä¸­å¿ƒ), Launch Excellence (å“è¶Šä¸Šå¸‚), Drug Life Cycle (ç”Ÿå‘½å‘¨æœŸ),
    Pharma Supply Chain (åŒ»è¯ä¾›åº”é“¾), DTP Pharmacy (DTPè¯æˆ¿), Internet Hospital (äº’è”ç½‘åŒ»é™¢), Pharmacy Retail Strategy (é›¶å”®æˆ˜ç•¥), Lower-tier Market (ä¸‹æ²‰å¸‚åœº),
    MNC China Strategy (è·¨å›½ä¼æˆ˜ç•¥), Local Biotech Rise (æœ¬åœŸBiotech), CXO Trends (CXOè¶‹åŠ¿), Pharma Licensing (BDäº¤æ˜“), Pharma M&A (åŒ»è¯å¹¶è´­),
    Cross-border Collaboration (è·¨å¢ƒåˆä½œ), Patent Cliff (ä¸“åˆ©æ‚¬å´–), Pharma Compliance (åŒ»è¯åˆè§„), ESG in Pharma (åŒ»è¯ESG), Pharma Talent Strategy (äººæ‰æˆ˜ç•¥),
    Consumer Health (æ¶ˆè´¹åŒ»ç–—), OTC Market (OTCå¸‚åœº), Medical Aesthetics (åŒ»ç¾è¶‹åŠ¿), TCM Internationalization (ä¸­åŒ»è¯å›½é™…åŒ–), Hospital Management (åŒ»é™¢ç®¡ç†),
    Private Healthcare (ç§ç«‹åŒ»ç–—), Commercial Health Insurance (å•†ä¸šåŒ»ä¿), Drug Regulatory Reforms (è¯ç›‘æ”¹é©), Patient Data Privacy (æ•°æ®éšç§), Pharma Globalization (è¯ä¼å‡ºæµ·)
]

**Current Focus**: [æ­¤å¤„å¡«å…¥ä½ æœ¬æ¬¡éšæœºé€‰ä¸­çš„ä¸»é¢˜]

### ç¬¬äºŒæ­¥ï¼šå®šå‘æ•è· (Targeted Search)
ç»“åˆéšæœºé€‰ä¸­çš„ä¸»é¢˜ï¼Œä½¿ç”¨ä»¥ä¸‹æŒ‡ä»¤è¿›è¡Œæœç´¢ã€‚
*(å°† `{Selected Theme}` æ›¿æ¢ä¸ºä½ åˆšæ‰é€‰ä¸­çš„ä¸»é¢˜è‹±æ–‡å)*

```text
(site:iqvia.com OR site:mckinsey.com OR site:bcg.com OR site:bain.com OR site:rolandberger.com OR site:deloitte.com OR site:lek.com OR site:zs.com OR site:pwc.com OR site:ey.com OR site:kpmg.com OR site:accenture.com OR site:kearney.com) (China Pharma OR ä¸­å›½åŒ»è¯) (2025 OR 2026) ({Selected Theme}) filetype:pdf
```

### ç¬¬ä¸‰æ­¥ï¼šä»·å€¼è¯„ä¼° (Evaluate)
é˜…è¯»æœç´¢ç»“æœã€‚
1.  **Variety Rule**: ä¸è¦æ€»æ˜¯åªçœ‹ç¬¬ä¸€ä¸ªç»“æœã€‚è¯·æµè§ˆå‰ 10 ä¸ªç»“æœï¼ŒéšæœºæŒ‘é€‰ä¸€ä¸ªä¸ `{Selected Theme}` é«˜åº¦ç›¸å…³çš„æŠ¥å‘Šã€‚
2.  **ç­›é€‰æ ‡å‡†**ï¼š
    *   å¿…é¡»æ¶µç›– 2024-2026 çš„æœ€æ–°æ•°æ®ã€‚
    *   å¿…é¡»åŒ…å«å…·ä½“çš„æ•°æ®å›¾è¡¨ï¼Œè€Œéçº¯æ–‡å­—æè¿°ã€‚

    *   pure marketing (å…¬å¸å®£ä¼ å†Œ)
    *   outdated (æ—§æ•°æ®)

### ç¬¬ä¸‰æ­¥ï¼šé“¾æ¥éªŒè¯ (Verify Link)
**CRITICAL**: åœ¨æœ€ç»ˆè¾“å‡ºä¹‹å‰ï¼Œå¿…é¡»éªŒè¯ PDF é“¾æ¥æ˜¯å¦æœ‰æ•ˆã€‚
1.  å°è¯•è®¿é—®è¯¥ URLã€‚
2.  å¦‚æœè¿”å› 404 æˆ–æ— æ³•è®¿é—®ï¼š
    *   **Action**: ä½¿ç”¨ `site:domain.com "report title"` é‡æ–°æœç´¢è¯¥æŠ¥å‘Šçš„æœ€æ–° Landing Pageã€‚
    *   **Fallback**: å¦‚æœæ‰¾ä¸åˆ° PDF ç›´é“¾ï¼Œè¯·æä¾›æŠ¥å‘Šçš„å®˜æ–¹ Landing Pageï¼ˆå‘å¸ƒé¡µï¼‰é“¾æ¥ã€‚
    *   **Advanced Recovery (é˜²çˆ¬è™«ç­–ç•¥)**:
        *   å¦‚æœ Landing Page å¯è®¿é—®ä½† PDF é“¾æ¥éšè—ï¼ˆå¦‚ Deloitte/McKinseyï¼‰ï¼Œ**å¿…é¡»**è°ƒç”¨ `browser_subagent` å·¥å…·ã€‚
        *   **Prompt**: "Navigate to [Landing Page URL]. Find the 'Download PDF' button (English or Chinese). Return the direct .pdf href."
        *   è·å–åˆ°çš„ç›´é“¾é€šå¸¸æ— é‰´æƒå³å¯è®¿é—®ï¼Œè¯·ç›´æ¥è¾“å‡ºè¯¥ .pdf é“¾æ¥ã€‚
    *   **Error Handling**: ç»ä¸è¦è¾“å‡ºæœªç»éªŒè¯çš„æ­»é“¾ã€‚

### ç¬¬å››æ­¥ï¼šæˆ˜ç•¥æç‚¼ (Summarize)
è¯·å¯¹é€‰ä¸­çš„è¿™ä»½æŠ¥å‘Šè¿›è¡Œ **â€œå’¨è¯¢é¡¾é—®å¼â€** è§£è¯»ï¼Œè¾“å‡ºä»¥ä¸‹ 3 ç‚¹ï¼ˆä¸­æ–‡è¾“å‡ºï¼‰ï¼š

1.  **The "So What?" (æ ¸å¿ƒæ´å¯Ÿ)**:
    *   ä¸è¦åºŸè¯ï¼Œç›´æ¥å‘Šè¯‰æˆ‘è¿™ä»½æŠ¥å‘Šæœ€åç›´è§‰æˆ–æœ€é‡è¦çš„ä¸€ä¸ªç»“è®ºæ˜¯ä»€ä¹ˆï¼Ÿ
    *   *Example: "è™½ç„¶ VBP å¯¼è‡´æˆç†Ÿäº§å“é”€å”®é¢æ–­å´–ä¸‹è·Œï¼Œä½† IQVIA æ•°æ®æ˜¾ç¤ºï¼ŒMNC é€šè¿‡â€˜é›¶å”®æ¸ é“â€™å’Œâ€˜æ•°å­—åŒ–â€™å®ç°äº† 15% çš„åˆ©æ¶¦å›è¡¥ã€‚"*

2.  **Key Numbers (å…³é”®æ•°æ®)**:
    *   åˆ—å‡ºæŠ¥å‘Šä¸­æ”¯æ’‘ä¸Šè¿°ç»“è®ºçš„ 1-2 ä¸ªç¡¬æ ¸æ•°æ®ã€‚
    *   *Example: "é™¢å¤–å¸‚åœºè§„æ¨¡å·²è¾¾ 800äº¿ RMBï¼ŒCAGR ä¿æŒåœ¨ 22%ã€‚"*

3.  **Application (é¢è¯•/å·¥ä½œæ€ä¹ˆç”¨)**:
    *   ã€å…³é”®ã€‘å°†æŠ¥å‘Šç»“è®ºè½¬åŒ–ä¸ºå…·ä½“çš„é¢è¯•è¯æœ¯æˆ–å‘¨æŠ¥æ±‡æŠ¥è¯ï¼ˆ**å¿…é¡»è¾“å‡ºä¸ºä¸­æ–‡ï¼Œä»¥ä¾¿ç›´æ¥ä½¿ç”¨**ï¼‰ã€‚
    *   *Example: "é¢è¯• Tips: å¦‚æœé‡åˆ°â€˜é›†é‡‡åå¦‚ä½•å¢é•¿â€™çš„ Caseï¼Œç›´æ¥å¼•ç”¨æ­¤æŠ¥å‘Šçš„â€˜å…¨æ¸ é“å¸ƒå±€æ¨¡å‹â€™ï¼Œèƒ½ä½“ç°ä½ çš„ Big Picture æ€ç»´ã€‚"*

## è¾“å‡ºç¤ºä¾‹ (Output Example)

**ã€æœ¬å‘¨ä¸¥é€‰ï¼šIQVIA 2025 ä¸­å›½åŒ»é™¢è¯å“ç»Ÿè®¡æŠ¥å‘Šã€‘**
ğŸ”— **ä¸‹è½½é“¾æ¥**: [ç‚¹å‡»ä¸‹è½½ PDF](URL)

ğŸ”¹ **æ ¸å¿ƒæ´å¯Ÿ**: åŒ»é™¢å¸‚åœºçš„â€œé©¬å¤ªæ•ˆåº”â€åŠ å‰§ã€‚è™½ç„¶æ€»ä½“å¤„æ–¹é‡ä¸Šæ¶¨ï¼Œä½†åˆ›æ–°è¯è¿›é™¢çš„å¹³å‡å‘¨æœŸåè€Œä» 6 ä¸ªæœˆæ‹‰é•¿åˆ°äº† 9 ä¸ªæœˆï¼Œæ„å‘³ç€ Launch Strategy å¿…é¡»å‰ç½®åˆ°ä¸´åºŠ II æœŸã€‚
ğŸ”¹ **å…³é”®æ•°æ®**: Top 100 åŒ»é™¢è´¡çŒ®äº†å…¨å¸‚åœº 45% çš„åˆ›æ–°è¯é”€å”®é¢ï¼›DTP è¯æˆ¿å¤„æ–¹å¤–æµç‡é¦–æ¬¡çªç ´ 18%ã€‚
ğŸ”¹ **å®æˆ˜åº”ç”¨**: é¢è¯•æ—¶å¦‚æœè¢«é—®åˆ° "Launch Excellence"ï¼Œåˆ«åªèŠå­¦æœ¯æ¨å¹¿ï¼Œä¸€å®šè¦å¼ºè°ƒ **â€œKA Access (é‡ç‚¹åŒ»é™¢å‡†å…¥)â€** å’Œ **â€œDTP é—­ç¯â€** çš„é‡è¦æ€§ã€‚
